Eisai Initiates Phase II Study of Dual Orexin Receptor Antagonist Lemborexant in People with Irregular SleepWake Rhythm Disorder ISWRD and Dementia

HATFIELD England November 8 2016 PRNewswire FOR UK MEDIA ONLY NOT FOR AUSTRIANSWISS JOURNALISTS Eisai today announces the initiation of a multicentre randomised phase II clinical study ...
Read the full story: Bioportfolio Latest News